Quinn Opportunity Partners LLC Sells 40,300 Shares of CVS Health Corporation $CVS

Quinn Opportunity Partners LLC lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 26.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 110,999 shares of the pharmacy operator’s stock after selling 40,300 shares during the period. Quinn Opportunity Partners LLC’s holdings in CVS Health were worth $8,368,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Brown Brothers Harriman & Co. increased its stake in shares of CVS Health by 34.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 9,768 shares of the pharmacy operator’s stock valued at $736,000 after acquiring an additional 2,524 shares during the last quarter. Chesapeake Capital Corp IL bought a new position in CVS Health during the 3rd quarter worth approximately $655,000. Pathstone Holdings LLC grew its holdings in CVS Health by 0.5% during the third quarter. Pathstone Holdings LLC now owns 180,776 shares of the pharmacy operator’s stock valued at $13,629,000 after purchasing an additional 973 shares during the period. Boston Partners increased its stake in CVS Health by 116.8% in the third quarter. Boston Partners now owns 104,491 shares of the pharmacy operator’s stock valued at $7,878,000 after purchasing an additional 56,296 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in CVS Health by 19.3% in the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 418,891 shares of the pharmacy operator’s stock worth $31,580,000 after purchasing an additional 67,668 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Up 0.1%

Shares of CVS Health stock opened at $76.14 on Friday. The stock has a market cap of $96.87 billion, a P/E ratio of 55.17, a P/E/G ratio of 0.79 and a beta of 0.49. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The business’s 50 day moving average is $78.17 and its 200-day moving average is $77.74.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same period last year, the business earned $1.19 earnings per share. The firm’s revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is currently 192.75%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CVS shares. TD Cowen reissued a “buy” rating on shares of CVS Health in a report on Friday. Truist Financial set a $100.00 price objective on CVS Health in a research note on Wednesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Argus decreased their target price on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Finally, Wolfe Research dropped their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $95.05.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.